Ms. Gail S. PageChembio Diagnostics, Inc. • August 7th, 2020 • Pharmaceutical preparations • New York
On behalf of Chembio Diagnostics Inc. (the “Company”), I am pleased to provide you with this letter agreement (this “Agreement”) setting forth the principal terms of the compensation package to be provided to you by the Company for your services as Executive Chair (“Executive Chair”) of the Company’s Board of Directors (the “Board”), which terms are effective as of June 15, 2020 and will continue up to the time of the Company’s 2021 Annual Meeting of Stockholders (the “Term”).
AMENDMENT TO LETTER AGREEMENTLetter Agreement • August 7th, 2020 • Chembio Diagnostics, Inc. • Pharmaceutical preparations • New York
This Amendment to Letter Agreement dated June 16, 2020 (this “Amendment”) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and Gail S. Page (“Page”), with respect to their Letter Agreement dated as of January 17, 2020 (the “Agreement”).
AMENDMENT TO LETTER AGREEMENTLetter Agreement • August 7th, 2020 • Chembio Diagnostics, Inc. • Pharmaceutical preparations • New York
This Amendment to Letter Agreement dated June 30, 2020 (this “Amendment”) is entered into between Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and Gail S. Page (“Page”), with respect to their Letter Agreement dated as of June 15, 2020 (the “Agreement”). Capitalized terms used in the Amendment and defined in the Agreement shall have the respective meanings ascribed to them in the Agreement.
